Eli Lilly and Insilico Medicine Expand AI Drug Discovery Partnership with Multibillion-Dollar Deal

Global pharmaceutical company Eli Lilly has expanded its partnership with Insilico Medicine, signing a potential multibillion-dollar deal to license an early-stage drug pipeline and utilize Insilico's artificial intelligence platform for drug development.

29 Mar, 11:00 — 30 Mar, 01:24

Post Share

Why this matters

This deal signifies a growing trend in the pharmaceutical industry to leverage artificial intelligence for accelerated drug discovery and development. It could lead to more efficient and cost-effective ways to bring new medicines to market, potentially transforming the landscape of pharmaceutical research and benefiting patients.

Key entitiesEli Lilly Insilico Medicine

The Story

What 9 sources agree on, dispute, and miss

What sources agree on

Eli Lilly and Insilico Medicine have expanded their partnership
The deal is potentially worth up to $2.75 billion
Eli Lilly will receive exclusive licenses to produce drugs developed by Insilico's AI platform
Insilico Medicine is a Hong Kong-listed biotech company specializing in AI

Key claims2 agreed · 2 unverified

✓

The deal is a potential multibillion-dollar agreement

agreed·SCMPseeking-alphacnbcReutersbloomberg+1

The Story

Analyzing sources…

Source Diversity

Excellent (76/100)

9 sources33/33

Spectrum spread— 3/5 buckets covered17/33

Far L

Left2

Left (2)

politikencnbc

Center4

Center (4)

SCMPReutersbloombergFT

Right3

Right (3)

channel-news-asiaberlingskeseeking-alpha

Far R

Geographic diversity— 6 regions26/34

US3Denmark2Hong Kong1Singapore1Intl1UK1

Political spectrum

LeftCenterRight

cnbc

scmp

reuters

bloomberg

Sources

Showing 6 of 9 sources

bloombergHigh15h ago

Lilly, Insilico Ink Deal on AI Drugs Worth Up to $2.75 Billion - Bloomberg.com

Lilly, Insilico Ink Deal on AI Drugs Worth Up to $2.75 Billion Bloomberg.com

Read full article →

FTVery High16h ago

Eli Lilly to sign $2bn deal for AI drug development with Hong Kong biotech

Global pharmaceutical companies are aggressively searching for new medicines in China

Read full article →

cnbcMostly Factual13h ago

Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market

U.S. pharmaceutical giant Eli Lilly will give Hong Kong-listed Insilico $115 million upfront to bring some of its AI-discovered drugs to the global market.

Read full article →

SCMPMostly Factual1h ago

Hong Kong-listed Insilico Medicine signs AI drug development deal with Eli Lilly

Insilico Medicine has signed a potential multibillion-dollar deal with Eli Lilly to license out an early-stage drug pipeline and provide its artificial intelligence platform services in research and development collaborations. Under the agreement announced on Monday, US-headquartered, Hong Kong-listed Insilico will receive an upfront payment of US$115 million. The deal could have a total value of around US$2.75 billion tied to development, regulatory and commercial milestones, plus tiered...

By Julie Zhang

Read full article →

channel-news-asiaMostly Factual3h ago

Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery

Read full article →

seeking-alphaMixed13h ago

Eli Lilly expands AI drug push with multibillion-dollar Insilico deal

Read full article →

Coverage Timeline

First report: FT · 29 Mar, 11:00|Full coverage: 9 · 14h|Window: 14h

Left-leaningCenterRight-leaning

FT29 Mar, 11:00First to report

Eli Lilly to sign $2bn deal for AI drug development with Hong Kong biotech

1h later

bloomberg29 Mar, 12:09

Lilly, Insilico Ink Deal on AI Drugs Worth Up to $2.75 Billion - Bloomberg.com

Reuters29 Mar, 12:50

Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly - Reuters

cnbc29 Mar, 13:36

Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market

seeking-alpha29 Mar, 13:47

Eli Lilly expands AI drug push with multibillion-dollar Insilico deal

2h later

berlingske29 Mar, 15:58

Novo-rival indgår milliardaftale med selskab med speciale i AI

politiken29 Mar, 16:05

Novo-rival indgår milliardaftale med selskab med speciale i ai

8h later

channel-news-asia30 Mar, 00:03

Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery

1h later

SCMP30 Mar, 01:24Latest update

Hong Kong-listed Insilico Medicine signs AI drug development deal with Eli Lilly

Story evolution

The initial narrative focused on the deal's size, which then evolved to include specific financial terms and the strategic implications of AI in drug development and global pharmaceutical trends.

Initial ReportingMarch 29, 11:00-12:50 UTC

Early reports from Bloomberg, Reuters, and FT announced the deal and its potential value, with FT adding context about global pharma interest in China.

Financial Details EmergeMarch 29, 13:30-16:00 UTC

CNBC provided more specific financial details, including the upfront payment, while Seeking Alpha and Berlingske focused on the strategic expansion.

Confirmation and Broader ContextMarch 30, 00:00-01:30 UTC

Channel News Asia and SCMP confirmed the partnership, with SCMP detailing the licensing of an early-stage pipeline and AI platform services.

	Reuters	bloomberg	FT	cnbc	SCMP	berlingske	politiken	channel-news-asia	seeking-alpha
The upfront payment of $115 million from Eli Lilly to Insilico
The broader trend of global pharmaceutical companies aggressively searching for new medicines in China

Eli Lilly and Insilico Medicine Expand AI Drug Discovery Partnership with Multibillion-Dollar Deal

Why this matters

The Story

What sources agree on

Key claims2 agreed · 2 unverified

The Story

Source Diversity

Source Diversity

Political spectrum

Sources

Lilly, Insilico Ink Deal on AI Drugs Worth Up to $2.75 Billion - Bloomberg.com

Eli Lilly to sign $2bn deal for AI drug development with Hong Kong biotech

Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market

Hong Kong-listed Insilico Medicine signs AI drug development deal with Eli Lilly

Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery

Eli Lilly expands AI drug push with multibillion-dollar Insilico deal

Coverage Timeline

Eli Lilly to sign $2bn deal for AI drug development with Hong Kong biotech

Lilly, Insilico Ink Deal on AI Drugs Worth Up to $2.75 Billion - Bloomberg.com

Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly - Reuters

Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market

Eli Lilly expands AI drug push with multibillion-dollar Insilico deal

Novo-rival indgår milliardaftale med selskab med speciale i AI

Novo-rival indgår milliardaftale med selskab med speciale i ai

Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery

Hong Kong-listed Insilico Medicine signs AI drug development deal with Eli Lilly

Story evolution

Related Stories

Herpetologist Karl Schmidt Dies Documenting Snakebite Effects

Air Canada Flight Attendant Solange Tremblay's Ongoing Recovery After LaGuardia Crash

Chinese Biotech Firm Hangzhou Diagens to Use AI for IVF Chromosome Testing

Hong Kong Continues to Address Challenges in Autism Support Services

Why this matters

Story evolution

The Story

What sources agree on

Key claims2 agreed · 2 unverified

Political spectrum

Coverage gaps

Coverage matrix